GSK said it could complete the deal this year, which may allow it to launch the two late-stage drugs, zidesamtinib and neladalkib, before the end of 2026, subject to approvals.
“GSK’s proven track record, infrastructure, and expertise will support the successful commercialisation of zidesamtinib and neladalkib, as well as accelerate advancement of our broader discovery pipeline,” Nuvalent CEO James Porter said in the statement.
The pharmaceutical industry has faced turbulence from US President Donald Trump’s tariff threats last year, aimed at encouraging investment in the United States and reducing drug prices.
READ ALSO: Cancer Researchers Present Advances And Emerging Treatments
GSK, along with other non-US pharmaceutical giants, agreed in December to lower the cost of its prescription medicines for American patients in exchange for tariff exemptions for three years.
Miels took the helm at GSK in January, replacing Emma Walmley after almost nine years as CEO. Miels was previously the group’s chief commercial officer.
AFP
The post Britain’s GSK To Buy US Cancer Specialist Nuvalent For $10.6bn appeared first on Channels Television.